University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Biao He, PhD

Biao He, PhD

Associate Adjunct Professor, Department of Surgery, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

The focus of my current research is to define the role of aberrant Hedgehog/Gli activation in chemo and EGFR-TKI resistance in lung cancer and mesothelioma, and to conduct preclinical evaluation of the novel Gli inhibitor that we have recently developed, as potential effective therapeutic treatments to reverse the resistance in lung cancer and mesothelioma. I have also been a PI and co-Investigator of several other research projects funded by NIH and foundations, including identification and validation of novel potential therapeutic targets in lung cancer and mesothelioma; the role of inflammation and epigenetic alterations in lung carcinogenesis; the elucidation of novel molecular mechanisms in lung and mesothelioma carcinogenesis; the identification and validation of prognostic and predictive markers; and the development of small molecule inhibitors of stem cell signaling pathways as potential leads for targeted cancer therapies. As a result, I produced many peer-reviewed publications and issued/pending patents from these projects.

Education

Tsinghua University, Beijing, China, BS, 1993, Biochemistry
Tsinghua University, Beijing, China, MS, 1995, Biochemistry
University of Virginia, VA, PhD, 2001, Molecular, Cell Biology and Genetics
Comprehensive Cancer Center, University of California, San Francisco, CA, Postdoctoral training, 2002, Molecular, Cell Biology and Signal Transduction


Professional Experience

  • 1994-1995
    Graduate Research Assistant, Department of Biology, Tsinghua University, Beijing, China
  • 1995-1996
    Graduate Research Assistant, Biological Timing Center, University of Virginia, VA
  • 1996-1997
    Graduate Teaching Assistant, Department of Biology, University of Virginia, VA
  • 1997-2001
    Graduate Research Assistant, Department of Biology, University of Virginia, VA
  • 2001-2002
    Postdoctoral Researcher, Cancer Center, University of California San Francisco, CA
  • 2002-2004
    Assistant Research Molecular Biologist, Cancer Center, Univ. of California San Francisco, CA
  • 2004-2009
    Assistant Adjunct Professor, Department of Surgery, University of California San Francisco, CA
  • 2009-present
    Associate Adjunct Professor, Department of Surgery, University of California San Francisco, CA

Honors & Awards

  • 1989
    Honor of Outstanding Student, Tsinghua University, Beijing, China
  • 1990
    Honor of Outstanding Student, Tsinghua University, Beijing, China
  • 1991
    Honor of Outstanding Student, Tsinghua University, Beijing, China
  • 1992
    Guanghua Scholarship, Tsinghua University, Beijing, China
  • 1993
    Honor of Outstanding Graduate, Tsinghua University, Beijing, China
  • 1995
    Hua Luogeng Memorial Fellowship, Tsinghua University, Beijing, China
  • 1995
    Fellowship, University of Virginia, Charlottesville, VA
  • 1996
    Fellowship, University of Virginia, Charlottesville, VA
  • 2004
    Barbara Isackson Endowed Research Fellow, University of California, San Francisco, CA
  • 2007
    Eileen Ludwig Award in Thoracic Oncology Research, Univ. of California, San Francisco, CA

Selected Publications

  • He B, You L, Uematsu K, Zang K, Xu Z, Costello JF, McCormick F & Jablons DM. SOCS-3 suppresses cell growth and is silenced by frequent hyper-methylation in human lung cancer, Proc. Natl. Acad. Sci. USA 2003, 100 (24): 14133-14138.
  • Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F & Jablons DM. Wnt Inhibitory Factor-1 (WIF-1) is silenced by promoter hypermethylation in human lung cancer, Cancer Research 2004, 64: 4717-4720.
  • He B, You L, Uematsu K, Zang K, Xu Z, Matsangou M, McCormick F & Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells, Neoplasia, 2004, 6: 7-14.
  • You L, He B, Uematsu K, Xu Z, McCormick F & Jablons DM. Inhibition of Wnt-1 signaling induces apoptosis in beta-Catenin-deficient mesothelioma cells, Cancer Research, 2004, 64: 3474-3478.
  • Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F & Jablons DM. Expression of the secreted frizzled-related protein (sFRP) family is down-regulated by methylation in human lung cancer and mesothelioma, Oncogene 2004, 23 (39): 6672-6676.
  • He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, Batra S, Rosell R & Jablons DM. Wnt signaling in stem cells and non small cell lung cancer. Clinical Lung Cancer 2005, 7(1): 54-60 (Cover of the issue)
  • He B, Lee AY, Dadfarmay S, You L, Xu Z, Mazieres J, Uematsu K, Reguart N, Mikami I, McCormick F & Jablons DM. SFRP4 is silenced by hypermethylation and induces apoptosis in β-catenin-deficient human mesothelioma cells, Cancer Research, 2005, 65 (3): 743-748.
  • He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, McCormick F & Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene, 2005, 24 (18): 3054-3058.
  • Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD & Scherle PA. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer, Cancer Cell, 2006, 10 (1): 39-50. (Cover of the Issue)
  • He B & Jablons DM. Wnt signaling in stem cells and lung cancer. Ernst Schering Foundation Symposium Proceedings 2006, 5: 27-58.
  • Raz DJ, He B, Rosell R & Jablons DM. Current concepts in bronchioloalveolar carcinoma biology. Clinical Cancer Research 2006, 12 (12): 3698-3704.
  • Lee AY, Raz DJ, He B & Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer 2007, 109 (8): 1454-1461.
  • Shi Y, He B, Kuchenbecher K, You L, Mikami I, Xu Z, Clement G, Lin Y, Beltran A, Okamoto J & Jablons DM. Inhibition of Wnt-2 and Galectin-3 synergistically de-stabilizes β-catenin and induces apoptosis in human colorectal cancer cells. International Journal of Cancer, 2007, 121: 1175-1181.
  • Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK & Jablons DM,. An antagonist of Dishevelled protein-protein interaction suppresses b-catenin-dependent tumor cell growth. Cancer Research, 2007, 67 (2): 573-579 (Cover of the Issue).
  • Raz DJ, Ray R, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R & Jablons DM. A multi-gene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clinical Cancer Research 2008, 14 (17): 5565-5570.
  • Okamoto J, Mikami I, Tominaga Y, Kuchenbecher K, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, *He B & Jablons DM. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. Journal of Thoracic Oncology 2008, 3 (10): 1089-1095. (*Corresponding author)
  • Lemjabbar-Alaoui H, van Zante A, Singer M, Xue Q, Qing Y, Tsay D, He B, Jablons DM & Rosen SD. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010, 29 (5):635-646.
  • Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, Beltran A, Johansson M, Coussens L, Clement G, Shi Y, Zhang F, Koizumi K, Shimizu K, Jablons D & He B. EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene 2010, August 9; doi:10.1038/onc.2010.330.
  • Mikami I, Zhang F, Okamoto J, Hirata T, Koizumi K, Shimizu K, Jablons D & He B. Inhibition of activated phosphatidylinositol 3-kinase/AKT signaling pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest. Oncology Reports 2010 (In Press).
  • Ray R, Jablons D & He B. Lung cancer therapeutics that target signaling pathways: an update. Expert Review of Respiratory Medicine 2010 (In Press).